These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16431115)

  • 1. Synthesis, in vitro pharmacology, and structure-activity relationships of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as mGluR2 antagonists.
    Yasuhara A; Sakagami K; Yoshikawa R; Chaki S; Nakamura M; Nakazato A
    Bioorg Med Chem; 2006 May; 14(10):3405-20. PubMed ID: 16431115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists.
    Nakazato A; Kumagai T; Sakagami K; Yoshikawa R; Suzuki Y; Chaki S; Ito H; Taguchi T; Nakanishi S; Okuyama S
    J Med Chem; 2000 Dec; 43(25):4893-909. PubMed ID: 11123999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
    Nakazato A; Sakagami K; Yasuhara A; Ohta H; Yoshikawa R; Itoh M; Nakamura M; Chaki S
    J Med Chem; 2004 Aug; 47(18):4570-87. PubMed ID: 15317467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.
    Monn JA; Prieto L; Taboada L; Hao J; Reinhard MR; Henry SS; Beadle CD; Walton L; Man T; Rudyk H; Clark B; Tupper D; Baker SR; Lamas C; Montero C; Marcos A; Blanco J; Bures M; Clawson DK; Atwell S; Lu F; Wang J; Russell M; Heinz BA; Wang X; Carter JH; Getman BG; Catlow JT; Swanson S; Johnson BG; Shaw DB; McKinzie DL
    J Med Chem; 2015 Sep; 58(18):7526-48. PubMed ID: 26313429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Pharmacological Characterization of C4
    Monn JA; Henry SS; Massey SM; Clawson DK; Chen Q; Diseroad BA; Bhardwaj RM; Atwell S; Lu F; Wang J; Russell M; Heinz BA; Wang XS; Carter JH; Getman BG; Adragni K; Broad LM; Sanger HE; Ursu D; Catlow JT; Swanson S; Johnson BG; Shaw DB; McKinzie DL; Hao J
    J Med Chem; 2018 Mar; 61(6):2303-2328. PubMed ID: 29350927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
    Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
    J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
    J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential.
    Yasuhara A; Nakamura M; Sakagami K; Shimazaki T; Yoshikawa R; Chaki S; Ohta H; Nakazato A
    Bioorg Med Chem; 2006 Jun; 14(12):4193-207. PubMed ID: 16487713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-HYDIA.
    Woltering TJ; Adam G; Huguenin P; Wichmann J; Kolczewski S; Gatti S; Bourson A; Kew JN; Richards G; Kemp JA; Mutel V; Knoflach F
    ChemMedChem; 2008 Feb; 3(2):323-35. PubMed ID: 18058780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.
    Chaki S; Yoshikawa R; Hirota S; Shimazaki T; Maeda M; Kawashima N; Yoshimizu T; Yasuhara A; Sakagami K; Okuyama S; Nakanishi S; Nakazato A
    Neuropharmacology; 2004 Mar; 46(4):457-67. PubMed ID: 14975669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
    Fell MJ; Perry KW; Falcone JF; Johnson BG; Barth VN; Rash KS; Lucaites VL; Threlkeld PG; Monn JA; McKinzie DL; Marek GJ; Svensson KA; Nelson DL
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1126-36. PubMed ID: 19755662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biology of the conformationally restricted ACPD analogue, 2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-I, a potent mGluR agonist.
    Kozikowski AP; Steensma D; Araldi GL; Tückmantel W; Wang S; Pshenichkin S; Surina E; Wroblewski JT
    J Med Chem; 1998 May; 41(10):1641-50. PubMed ID: 9572889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of mgs0039 (3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid), a potent metabotropic glutamate receptor antagonist.
    Nakamura M; Kawakita Y; Yasuhara A; Fukasawa Y; Yoshida K; Sakagami K; Nakazato A
    Drug Metab Dispos; 2006 Mar; 34(3):369-74. PubMed ID: 16326817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats.
    Koltunowska D; Gibula-Bruzda E; Kotlinska JH
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():242-9. PubMed ID: 23623810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonists.
    Monn JA; Valli MJ; Massey SM; Hao J; Reinhard MR; Bures MG; Heinz BA; Wang X; Carter JH; Getman BG; Stephenson GA; Herin M; Catlow JT; Swanson S; Johnson BG; McKinzie DL; Henry SS
    J Med Chem; 2013 Jun; 56(11):4442-55. PubMed ID: 23675965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational Pharmacology of the Metabotropic Glutamate 2 Receptor-Preferring Agonist LY2812223 in the Animal and Human Brain.
    Felder CC; Schober DA; Tu Y; Quets A; Xiao H; Watt M; Siuda E; Nisenbaum E; Xiang C; Heinz B; Prieto L; McKinzie DL; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):190-197. PubMed ID: 28138041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.
    Monn JA; Valli MJ; Massey SM; Wright RA; Salhoff CR; Johnson BG; Howe T; Alt CA; Rhodes GA; Robey RL; Griffey KR; Tizzano JP; Kallman MJ; Helton DR; Schoepp DD
    J Med Chem; 1997 Feb; 40(4):528-37. PubMed ID: 9046344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test.
    Shimazaki T; Iijima M; Chaki S
    Eur J Pharmacol; 2004 Oct; 501(1-3):121-5. PubMed ID: 15464070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu
    Witkin JM; Ornstein PL; Mitch CH; Li R; Smith SC; Heinz BA; Wang XS; Xiang C; Carter JH; Anderson WH; Li X; Broad LM; Pasqui F; Fitzjohn SM; Sanger HE; Smith JL; Catlow J; Swanson S; Monn JA
    Neuropharmacology; 2017 Mar; 115():100-114. PubMed ID: 26748052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740.
    Procaccini C; Maksimovic M; Aitta-Aho T; Korpi ER; Linden AM
    Neuroscience; 2013 Oct; 250():189-200. PubMed ID: 23867766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.